The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia.

Slides:

Advertisements

Similar presentations

Effect of SGLT-2 inhibitors is different from that of carbohydrate restriction Although restriction of carbohydarate reduces post-prandial.

Advertisements

Diabetes and CKD- The update

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Cardiovascular Challenges in Diabetes

EMPA-REG OUTCOME: The Endocrinologist's Point of View

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Mancia and Grassi (2018) Diabetologia DOI /s

Empagliflozin (Jardiance®)

Nat. Rev. Nephrol. doi: /nrneph

Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

New Data on the Safety of SGLT2 Inhibitors

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Ghrelin—a new player in glucose homeostasis?

Updates on CVOT Data and Clinical Comparisons That Matter

Global Projections for Diabetes:

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Updates on Outcomes for Novel T2D Therapies

Bart Staels, PhD The American Journal of Medicine

Understanding EMPA-REG OUTCOME

Figure 1 Role of the kidney in glucose homeostasis

Nat. Rev. Nephrol. doi: /nrneph

Diabetes mellitus SGLT2 inhibitors: Novel concepts (cont’d):

SGLT2 Inhibitors and CV Outcomes

Emerging CVOT Data and Clinical Application

Impacting CV Risk With Diabetes Medications

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Impacting CV Risk With Diabetes Medications

Introduction The American Journal of Medicine

Clinical Application of New CV Outcomes Data

EMPA-REG OUTCOME: The Nephrologist's Point of View

T2DM and CV Outcomes Trials: A Deep Dive!

A Deep Dive Into CVOTs.

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Figure 2 Glucose handling by the kidney

Tackling CV Risk in T2DM.

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Breaking Down the CVOTs

Gregory Baud, M. D. , Violeta Raverdy, M. D. , Caroline Bonner, Ph. D

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.

Volume 26, Issue 1, Pages (July 2017)

Antihyperglycemic Therapy

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Updates From ACC.

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Gary C.W. Chan, Sydney C.W. Tang Kidney International

Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD

2015 EASD In Review: CV Risk management in t2dm

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management G. B. John Mancini, MD, Alice.

Diabetes action Canada annual workshop

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Emerging Advances in Reducing Renal Complications of T2D

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Presentation transcript:

The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia DOI 10.1007/s00125-018-4669-0 © Springer-Verlag GmbH Germany, part of Springer Nature 2018

Physiological mechanisms implicated in changes in renal function following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia DOI 10.1007/s00125-018-4669-0 © Springer-Verlag GmbH Germany, part of Springer Nature 2018

Renal outcomes in the EMPA-REG OUTCOME trial and CANVAS Empagliflozin Canagliflozin Thomas and Cherney (2018) Diabetologia DOI 10.1007/s00125-018-4669-0 © Springer-Verlag GmbH Germany, part of Springer Nature 2018